Exposure to persistent organic pollutants and the risk of type 2 diabetes: a case-cohort study.


Journal

Diabetes & metabolism
ISSN: 1878-1780
Titre abrégé: Diabetes Metab
Pays: France
ID NLM: 9607599

Informations de publication

Date de publication:
09 2021
Historique:
received: 01 11 2020
revised: 06 01 2021
accepted: 09 01 2021
pubmed: 31 1 2021
medline: 15 12 2021
entrez: 30 1 2021
Statut: ppublish

Résumé

To explore exposure to 22 persistent organic pollutants (POPs) and incident type 2 diabetes in a population-based, prospective cohort. This case-cohort study on 753 participants without type 2 diabetes at baseline, was followed-up over nine years, as part of the French D.E.S.I.R. cohort. We measured 22 POPs in fasting serum at baseline. The associations between baseline POP concentrations, pre-adjusted for lipids, BMI, age and sex, with incident type 2 diabetes, were assessed using Prentice-weighted Cox regression models (time scale: age), adjusted for traditional confounding factors. POPs were also modelled summed in functional groups: polychlorinated biphenyls (∑PCB) and organochlorines (∑OC) and also individually, after log-transformation, in adjusted Cox models. There were 200 incident diabetes cases over nine years. Pre-adjusted POP concentrations were not related to diabetes risk for any of the 22 POPs examined. The fully-adjusted hazard ratios (HRs) per interquartile range of the pre-adjusted POPs, ranged from 0.87 (95% CI: 0.64,1.19) to 1.22 (0.93,1.59,). For dichlorodiphenyldichloroethylene (p, p'-DDE) and dichlorodiphenyltrichloroethane (p, p'-DDT), the HRs were 1.09 (0.83,1.43) and 0.89 (0.70,1.13), respectively. The HRs for PeCB, HCB, β-HCH, γ-HCH, oxychlordane, trans-nonachlor were 0.98 (0.85,1.13), 1.06 (0.84,1.33), 1.22 (0.93,1.59), 1.13 (0.89,1.42), 1.00 (0.76,1.31), 0.86 (0.66,1.13), respectively. HRs for ∑PCB, ∑OC and for individual log-transformed POPs did not differ significantly from one. We did not observe any relations between exposure to POPs and diabetes in this population-based cohort. These results do not support causal inferences reported in previous studies linking serum POP concentrations and diabetes risk.

Identifiants

pubmed: 33515717
pii: S1262-3636(21)00017-3
doi: 10.1016/j.diabet.2021.101234
pii:
doi:

Substances chimiques

Environmental Pollutants 0
Hydrocarbons, Chlorinated 0
Dichlorodiphenyl Dichloroethylene 4M7FS82U08
Polychlorinated Biphenyls DFC2HB4I0K

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

101234

Informations de copyright

Copyright © 2021 Elsevier Masson SAS. All rights reserved.

Auteurs

Dianna J Magliano (DJ)

Baker Heart and Diabetes Institute, Diabetes and Population Health, Melbourne, Australia; Monash University, Department of Epidemiology and Preventive Medicine, Melbourne, Australia. Electronic address: dianna.magliano@baker.edu.au.

Fanny Rancière (F)

Université de Paris, Centre of Research in Epidemiology and Statistics (CRESS), Inserm, F-75004 Paris, France; Université de Paris, Faculté de Pharmacie de Paris, Paris, France.

Rémy Slama (R)

Inserm-Centre National de la Recherche Scientifique (CNRS) and Université Grenoble-Alpes Joint Research Center, Institute for Advanced Biosciences (IAB), U1209, Team of Environmental Epidemiology Applied to Reproduction and Respiratory Health, Grenoble, France; Université Grenoble-Alpes, IAB, Grenoble, France.

Ronan Roussel (R)

Inserm, UMRS 1138, Centre de Recherche des Cordeliers, Paris, France; Assistance Publique-Hôpitaux de Paris, Bichat Hospital, DHU FIRE, Diabetology, Endocrinology and Nutrition, Paris, France; Université de Paris, UFR de Médecine, Paris, France.

Hannu Kiviranta (H)

National Institute of Health and Welfare, Kuopio, Finland.

Xavier Coumoul (X)

Université de Paris, T3S, Inserm UMR S-1124, F-75006 Paris, France.

Beverley Balkau (B)

Université Paris-Saclay, UVSQ, Univ. Paris-Sud, Inserm, Clinical Epidemiology, CESP, Villejuif, France.

Jérémie Botton (J)

EPI-PHARE Scientific Interest Group in Epidemiology of Health Products, French National Agency for the Safety of Medicines and Health Products and the French National Health Insurance, Saint-Denis, Ile-de-France, France; IRSA, La Riche, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH